• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

    0.2200 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Mainz Biomed N.V. - Ordinary Shares

    < Previous 1 2 3 4 Next >
    Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
    GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
    Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
    PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Provides Half Year 2024 Corporate Update
    Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Reports Results of 2024 Annual General Meeting
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
    The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Reports Full Year 2023 Financial Results
    ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
    Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
    Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Provides Year-End Corporate Review 2023
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
    Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and... 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
    From Mainz BioMed NV
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.